Floatz logo

Evomela

Primary Immune Deficiency Disorder

Paul SzabolcsPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Primary Immune Deficiency Disorder cohort.

Asset / SponsorPhaseRating
Busulphan
medac GmbH
Phase 2B
Fludarabine
Paul Szabolcs
Phase 2B
Treosulfan
medac GmbH
Phase 2B
Thiotepa
Paul Szabolcs
Phase 2CCC
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Paul Szabolcs
Phase 2CCC

View all 15 →

Same molecule, other indications

Evomela is also rated in:

diffuse large B-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
myeloproliferative neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →